5 Stocks Boosting The Drugs Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 79 points (0.5%) at 15,295 as of Wednesday, May 15, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 1,703 issues advancing vs. 1,237 declining with 128 unchanged.

The Drugs industry currently is unchanged today versus the S&P 500, which is up 0.6%. Top gainers within the industry include Eli Lilly and Company ( LLY), up 2.0%, Abbott Laboratories ( ABT), up 1.6%, GlaxoSmithKline ( GSK), up 1.5%, Novartis ( NVS), up 1.4% and AstraZeneca ( AZN), up 0.8%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Bristol-Myers Squibb Company ( BMY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Bristol-Myers Squibb Company is up $3.02 (7.15) to $45.23 on heavy volume Thus far, 17.7 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 9.1 million shares. The stock has ranged in price between $42.16-$45.36 after having opened the day at $42.22 as compared to the previous trading day's close of $42.21.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $67.2 billion and is part of the health care sector. The company has a P/E ratio of 46.0, above the S&P 500 P/E ratio of 17.7. Shares are up 29.5% year to date as of the close of trading on Tuesday. Currently there are 7 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 13 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

4. As of noon trading, Gilead ( GILD) is up $0.56 (1.00) to $56.81 on average volume Thus far, 8.2 million shares of Gilead exchanged hands as compared to its average daily volume of 11.5 million shares. The stock has ranged in price between $55.09-$57.10 after having opened the day at $56.34 as compared to the previous trading day's close of $56.25.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $83.1 billion and is part of the health care sector. The company has a P/E ratio of 30.4, above the S&P 500 P/E ratio of 17.7. Shares are up 48.3% year to date as of the close of trading on Tuesday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, increase in net income and growth in earnings per share. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Gilead Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

3. As of noon trading, Merck ( MRK) is up $0.56 (1.20) to $47.21 on average volume Thus far, 6.7 million shares of Merck exchanged hands as compared to its average daily volume of 16.3 million shares. The stock has ranged in price between $46.46-$47.24 after having opened the day at $46.75 as compared to the previous trading day's close of $46.65.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $139.4 billion and is part of the health care sector. The company has a P/E ratio of 23.6, above the S&P 500 P/E ratio of 17.7. Shares are up 13.9% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Merck a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Merck Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

2. As of noon trading, Johnson & Johnson ( JNJ) is up $0.84 (0.97) to $87.81 on average volume Thus far, 4.1 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 9.6 million shares. The stock has ranged in price between $86.94-$87.87 after having opened the day at $87.02 as compared to the previous trading day's close of $86.97.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $241.1 billion and is part of the health care sector. The company has a P/E ratio of 23.4, above the S&P 500 P/E ratio of 17.7. Shares are up 24.1% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Johnson & Johnson Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

1. As of noon trading, Pfizer ( PFE) is up $0.24 (0.82) to $29.64 on average volume Thus far, 15.9 million shares of Pfizer exchanged hands as compared to its average daily volume of 32.2 million shares. The stock has ranged in price between $29.18-$29.66 after having opened the day at $29.40 as compared to the previous trading day's close of $29.40.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $208.3 billion and is part of the health care sector. The company has a P/E ratio of 20.7, above the S&P 500 P/E ratio of 17.7. Shares are up 17.2% year to date as of the close of trading on Tuesday. Currently there are 14 analysts that rate Pfizer a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Pfizer Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2